Transaction DateRecipientSharesTypePriceValue
21st December 2020David S. Richmond42,450Open or private sale$1.03$43,723.50
16th December 2020David S. Richmond100,000Open or private sale$1.02$102,360.00
16th December 2020David S. Richmond100,000Open or private sale$1.02$102,360.00
16th December 2020David S. Richmond185,855Open or private sale$1.01$187,806.48
16th December 2020David S. Richmond136,021Open or private sale$1.01$137,122.77
15th December 2020David S. Richmond234,145Open or private sale$1.11$259,128.27
15th December 2020David S. Richmond43,979Open or private sale$1.10$48,376.90
11th December 2020Allen Nissenson1,488Grant/award etc.$0.00
11th December 2020Andrea Heslin Smiley18,601Grant/award etc.$1.12$20,833.12
9th December 2020Benjamin Wolin2,778Open or private sale$29.61$82,269.91
Rockwell Medical
Rockwell Medical logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Rockwell Medical, Inc. engages in targeting end-stage renal disease and chronic kidney disease. Its dialysis products include hemodialysis concentrates, citrapure, dri-sate, safety data sheets,ancillary products, and renal pure. The company was founded by Robert L. Chioini in January 1995.

Ticker: RMTI
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1041024
Employees: 299
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $27 M (0%)
Inventory, Net: $5 M (24%)
Assets, Current: $52 M (39%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $561 Th (28%)
Assets: $59 M (32%)
Accounts Payable, Current: $3 M (9%)
Accrued Liabilities, Current: $4 M (0%)
Liabilities, Current: $11 M (-7%)
Liabilities: $42 M (76%)
Common Stock, Shares, Issued: $70 M (7%)
Retained Earnings (Accumulated Deficit): $321 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $46 Th (-12%)
Stockholders' Equity (Parent): $16 M (0%)
Liabilities and Equity: $59 M (32%)
Cost of Revenue: $15 M (-49%)
Gross Margin: $881 Th (-55%)
Research and Development: $2 M (-52%)
Sales and Marketing: $2 M (-50%)
General and Administrative Expenses: $3 M (-64%)
Operating Income/Loss: $6 M (-58%)